Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | May 18, 2011 | May 19, 2011 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director · 10% owner | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · Co-Chief Executive Officer · 10% owner | June 12, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTUITIVE SURGICAL INC
Report date May 18, 2011 · Filed May 19, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2011-05-18 transaction · row 1
1 source rowRow 1 · 2011-05-18 · Exercise / conversion · Acquired 1,000 · Balance 1,000 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.09 · Expires 2015-05-20 | Direct | 0 |
Reported balance
After 2011-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2011-05-18 · Exercise / conversion · Disposed 1,000 · Balance 0 F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 12,495 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 12,495 · Balance 12,495 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Summit Therapeutics Inc.
Report date June 12, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 573,883,879 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 3,810,000 · Balance 573,883,879 |
| Common StockSEC Table I · non-derivative | IndirectBy the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee | 25,824,474 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,824,474 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectImmediate family member of Spouse | 76,680 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,680 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 31,000 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 31,000 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee | 10,199,776 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,199,776 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Achaogen, Inc.
Report date March 18, 2019 · Filed March 20, 2019
Section 16 reporting ended · disclosed 2019-03-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 5,555,414 |
Ending reported balance
After 2019-03-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-18 · Sale · Disposed 271,879 · Balance 6,561,423 Row 2 · 2019-03-19 · Sale · Disposed 956,009 · Balance 5,605,414 Row 3 · 2019-03-20 · Sale · Disposed 50,000 · Balance 5,555,414 |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 30,000 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 30,000 F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 100,255 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 100,255 F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 72,170 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 72,170 F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director.
F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President.
F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2017 Filed May 3, 2017 00:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 19,348 | $23.81 | $460,714.58 |
DisclosureSEC source: 0001209191-17-029465 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,977,927 F1 · price: This is the weighted average purchase price of the shares, which ranged from $23.362 to $23.989 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 28, 2017 Filed May 3, 2017 00:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 35,000 | $24.00 | $840,000.00 |
DisclosureSEC source: 0001209191-17-029465 · doc4.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 35,000 F2 · ownership.nature: Shares are held by Genius Accelerated LLC, of which the Reporting Person is the sole member and beneficiary. Read SEC document |
| April 28, 2017 Filed May 3, 2017 00:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 25,000 | $23.85 | $596,250.00 |
DisclosureSEC source: 0001209191-17-029465 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,958,579 Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 01:14 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 200 | $22.95 | $4,590.00 |
DisclosureSEC source: 0001209191-17-028533 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,933,579 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 01:14 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 10,000 | $24.47 | $244,690.00 |
DisclosureSEC source: 0001209191-17-028533 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,933,379 F2 · price: This is the weighted average purchase price of the shares, which ranged from $24.45 to $24.47 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 25, 2017 Filed Apr 28, 2017 01:14 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 25,187 | $24.94 | $628,113.41 |
DisclosureSEC source: 0001209191-17-028533 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,923,379 F1 · price: This is the weighted average purchase price of the shares, which ranged from $24.841 to $24.978 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 19, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 37,905 | $25.37 | $961,801.47 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 9 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,898,192 F9 · price: This is the weighted average purchase price of the shares, which ranged from $25.134 to $25.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 19, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 26,000 | $24.35 | $633,048.00 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 8 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,860,287 F8 · price: This is the weighted average purchase price of the shares, which ranged from $23.966 to $24.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 19, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 53,228 | $23.28 | $1,239,360.75 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 7 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,834,287 F7 · price: This is the weighted average purchase price of the shares, which ranged from $22.84 to $23.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 19, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 32,990 | $22.24 | $733,532.65 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,781,059 F6 · price: This is the weighted average purchase price of the shares, which ranged from $21.835 to $22.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 28,000 | $26.02 | $728,588.00 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,748,069 F5 · price: This is the weighted average purchase price of the shares, which ranged from $25.75 to $26.651 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 33,819 | $25.06 | $847,436.50 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,720,069 F4 · price: This is the weighted average purchase price of the shares, which ranged from $24.66 to $25.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 73,900 | $25.39 | $1,876,173.20 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,686,250 F3 · price: This is the weighted average purchase price of the shares, which ranged from $24.982 to $25.815 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 10,500 | $24.34 | $255,591.00 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612,350 F2 · price: This is the weighted average purchase price of the shares, which ranged from $23.97 to $24.918 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 23:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 22,900 | $23.15 | $530,180.80 |
DisclosureSEC source: 0001209191-17-027595 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,601,850 F1 · price: This is the weighted average purchase price of the shares, which ranged from $22.925 to $23.913 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 01:43 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 22,764 | $21.40 | $487,081.31 |
DisclosureSEC source: 0001209191-17-026471 · doc4.xml · nonDerivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,578,950 F6 · price: This is the weighted average purchase price of the shares, which ranged from $21.13 to $21.616 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 01:43 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 9,200 | $20.38 | $187,450.00 |
DisclosureSEC source: 0001209191-17-026471 · doc4.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,556,186 F5 · price: This is the weighted average purchase price of the shares, which ranged from $20.05 to $20.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 07, 2017 Filed Apr 11, 2017 01:43 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 94,100 | $19.59 | $1,843,795.40 |
DisclosureSEC source: 0001209191-17-026471 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,546,986 F4 · price: This is the weighted average purchase price of the shares, which ranged from $19.079 to $20.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 06, 2017 Filed Apr 11, 2017 01:43 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 44,200 | $19.70 | $870,872.60 |
DisclosureSEC source: 0001209191-17-026471 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,452,886 F3 · price: This is the weighted average purchase price of the shares, which ranged from $19.125 to $19.976 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 06, 2017 Filed Apr 11, 2017 01:43 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 21,200 | $18.54 | $393,048.00 |
DisclosureSEC source: 0001209191-17-026471 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,408,686 F1 · price: This is the weighted average purchase price of the shares, which ranged from $18.122 to $18.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. F2 · balance_after: Includes 9,000 shares purchased by the Reporting Person that were inadvertently omitted from previous reports. Read SEC document |
| March 18, 2017 Filed Mar 21, 2017 01:50 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 105,486 | $23.01 | $2,427,127.37 |
DisclosureSEC source: 0001209191-17-021890 · doc4.xml · nonDerivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,378,486 F5 · price: This is the weighted average purchase price of the shares, which ranged from $22.40 to $23.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 01:50 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 25,859 | $24.07 | $622,451.99 |
DisclosureSEC source: 0001209191-17-021890 · doc4.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,273,000 F4 · price: This is the weighted average purchase price of the shares, which ranged from $23.71 to $24.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 16, 2017 Filed Mar 21, 2017 01:50 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 3,500 | $24.93 | $87,265.50 |
DisclosureSEC source: 0001209191-17-021890 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,247,141 F3 · price: This is the weighted average purchase price of the shares, which ranged from $24.89 to $24.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 16, 2017 Filed Mar 21, 2017 01:50 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 69,162 | $24.14 | $1,669,847.33 |
DisclosureSEC source: 0001209191-17-021890 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,243,641 F2 · price: This is the weighted average purchase price of the shares, which ranged from $23.66 to $24.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 16, 2017 Filed Mar 21, 2017 01:50 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,120 | $22.54 | $25,239.20 |
DisclosureSEC source: 0001209191-17-021890 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174,479 F1 · price: This is the weighted average purchase price of the shares, which ranged from $22.45 to $23.248 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| February 09, 2017 Filed Feb 22, 2017 19:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 41,624 | $11.64 | $484,503.36 |
DisclosureSEC source: 0001209191-17-013100 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,173,359 Read SEC document |
| May 18, 2011 Filed May 19, 2011 18:00 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $47.09 | $0.00 |
DisclosureSEC source: 0001252986-11-000059 · edgardoc.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2015-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. Read SEC document |
| May 18, 2011 Filed May 19, 2011 18:00 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionCommon Stock | 1,000 | $47.09 | $47,090.00 |
DisclosureSEC source: 0001252986-11-000059 · edgardoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2011 Filed May 4, 2011 20:04 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $47.09 | $0.00 |
DisclosureSEC source: 0001252986-11-000057 · edgardoc.xml · derivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 2,000 shares Expires 2015-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. Read SEC document |
| May 03, 2011 Filed May 4, 2011 20:04 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 2,000 | $354.46 | $708,920.20 |
DisclosureSEC source: 0001252986-11-000057 · edgardoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 03, 2011 Filed May 4, 2011 20:04 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionCommon Stock | 2,000 | $47.09 | $94,180.00 |
DisclosureSEC source: 0001252986-11-000057 · edgardoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $47.09 | $0.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · derivative · entry 12 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 2,500 shares Expires 2015-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 1,757 | $333.52 | $585,994.64 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 11 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 0 Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 800 | $334.27 | $267,416.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 10 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 1,757 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest in the shares. Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 843 | $335.05 | $282,447.15 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 9 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2,557 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest in the shares. Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | GiftCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 8 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 300 | $336.30 | $100,890.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 7 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 100 | $336.29 | $33,629.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550 Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 300 | $336.28 | $100,884.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 100 | $336.21 | $33,621.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950 Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 795 | $336.00 | $267,120.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050 Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 905 | $336.20 | $304,261.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,845 Read SEC document |
| February 09, 2011 Filed Feb 10, 2011 17:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionCommon Stock | 2,500 | $47.09 | $117,725.00 |
DisclosureSEC source: 0001252986-11-000012 · edgardoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2011 Filed Feb 9, 2011 18:30 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $47.09 | $0.00 |
DisclosureSEC source: 0001252986-11-000011 · edgardoc.xml · derivative · entry 15 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 2,000 shares Expires 2015-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. Read SEC document |
| February 08, 2011 Filed Feb 9, 2011 18:30 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 300 | $336.55 | $100,965.00 |
DisclosureSEC source: 0001252986-11-000011 · edgardoc.xml · nonDerivative · entry 13 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Read SEC document |
| February 08, 2011 Filed Feb 9, 2011 18:30 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 100 | $336.98 | $33,698.00 |
DisclosureSEC source: 0001252986-11-000011 · edgardoc.xml · nonDerivative · entry 12 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550 Read SEC document |
| February 08, 2011 Filed Feb 9, 2011 18:30 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 300 | $336.60 | $100,980.00 |
DisclosureSEC source: 0001252986-11-000011 · edgardoc.xml · nonDerivative · entry 11 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Read SEC document |
| February 08, 2011 Filed Feb 9, 2011 18:30 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 600 | $336.55 | $201,930.00 |
DisclosureSEC source: 0001252986-11-000011 · edgardoc.xml · nonDerivative · entry 10 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950 Read SEC document |
| February 08, 2011 Filed Feb 9, 2011 18:30 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 100 | $336.56 | $33,656.00 |
DisclosureSEC source: 0001252986-11-000011 · edgardoc.xml · nonDerivative · entry 9 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550 Read SEC document |
| February 08, 2011 Filed Feb 9, 2011 18:30 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 100 | $336.59 | $33,659.00 |
DisclosureSEC source: 0001252986-11-000011 · edgardoc.xml · nonDerivative · entry 8 DUGGAN ROBERT W · CIK 0001055919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.